Incyte Corp. (NASDAQ:INCY) had its target price boosted by JMP Securities from $100.00 to $110.00 in a research report issued on Monday. The firm presently has a “market outperform” rating on the biopharmaceutical company’s stock. JMP Securities’ price target would indicate a potential upside of 13.55% from the company’s current price.

A number of other research analysts have also weighed in on the company. Zacks Investment Research lowered Incyte Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, August 16th. Royal Bank Of Canada started coverage on Incyte Corp. in a report on Tuesday, July 12th. They set an “outperform” rating and a $105.00 target price on the stock. SunTrust Banks Inc. started coverage on Incyte Corp. in a report on Friday, August 5th. They set a “buy” rating and a $105.00 target price on the stock. Piper Jaffray Cos. set a $102.00 target price on Incyte Corp. and gave the stock a “buy” rating in a report on Tuesday, August 16th. Finally, Raymond James Financial Inc. raised Incyte Corp. from a “market perform” rating to an “outperform” rating and set a $115.00 target price on the stock in a report on Thursday, September 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twenty-one have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $105.40.

Analyst Recommendations for Incyte Corp. (NASDAQ:INCY)

Shares of Incyte Corp. (NASDAQ:INCY) traded down 1.21% during trading on Monday, reaching $96.65. The company’s stock had a trading volume of 715,078 shares. The stock’s 50 day moving average price is $85.39 and its 200 day moving average price is $80.88. Incyte Corp. has a 52 week low of $55.00 and a 52 week high of $124.98. The company has a market cap of $18.17 billion, a PE ratio of 262.64 and a beta of 0.53.

Incyte Corp. (NASDAQ:INCY) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.20. The business had revenue of $208 million for the quarter, compared to analyst estimates of $236.91 million. Incyte Corp. had a return on equity of 37.76% and a net margin of 7.87%. The firm’s revenue was up 51.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.05 EPS. Equities research analysts predict that Incyte Corp. will post $0.19 EPS for the current year.

In other Incyte Corp. news, EVP Paula J. Swain sold 60,000 shares of the stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $90.00, for a total value of $5,400,000.00. Following the completion of the transaction, the executive vice president now directly owns 89,248 shares in the company, valued at $8,032,320. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Reid M. Huber sold 10,000 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $87.96, for a total value of $879,600.00. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of INCY. Vanguard Group Inc. increased its position in Incyte Corp. by 2.9% in the second quarter. Vanguard Group Inc. now owns 11,973,101 shares of the biopharmaceutical company’s stock valued at $957,608,000 after buying an additional 340,717 shares in the last quarter. Capital World Investors boosted its stake in shares of Incyte Corp. by 1.3% in the second quarter. Capital World Investors now owns 10,686,491 shares of the biopharmaceutical company’s stock valued at $854,706,000 after buying an additional 134,000 shares during the last quarter. Capital International Investors boosted its stake in shares of Incyte Corp. by 9.2% in the second quarter. Capital International Investors now owns 5,918,033 shares of the biopharmaceutical company’s stock valued at $473,324,000 after buying an additional 499,536 shares during the last quarter. FMR LLC boosted its stake in shares of Incyte Corp. by 2.1% in the second quarter. FMR LLC now owns 4,971,659 shares of the biopharmaceutical company’s stock valued at $397,633,000 after buying an additional 100,334 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in shares of Incyte Corp. by 5.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 4,143,431 shares of the biopharmaceutical company’s stock valued at $331,392,000 after buying an additional 207,712 shares during the last quarter. Hedge funds and other institutional investors own 92.32% of the company’s stock.

Incyte Corp. Company Profile

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

5 Day Chart for NASDAQ:INCY

Receive News & Stock Ratings for Incyte Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corp. and related stocks with our FREE daily email newsletter.